Erythrityl tetranitrate: Uses, Side Effects, Dosage Info

Introduction

Erythrityl tetranitrate, also known as ETN or 1,2,3,4-Butanetetralyl tetranitrate, is a vasodilator medication used to treat angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. Erythrityl tetranitrate belongs to a class of drugs called nitrates, which work by relaxing the blood vessels to improve blood flow and oxygen delivery to the heart.

Chemical and Physical Properties

Erythrityl tetranitrate has the molecular formula C4H6N4O12 and a molecular weight of 302.11 g/mol. It is an odorless, white crystalline solid at room temperature. ETN is soluble in acetone and other ketones but has limited solubility in water. The compound has four nitrate ester groups attached to an erythritol backbone, giving it unique chemical and physical properties.

Mechanism of Action

As a nitrate vasodilator, erythrityl tetranitrate works by releasing nitric oxide (NO) in the body. NO activates the enzyme guanylate cyclase, leading to an increase in cyclic guanosine monophosphate (cGMP) levels. cGMP causes relaxation of the smooth muscle cells in blood vessels, resulting in vasodilation. By dilating the arteries and veins, erythrityl tetranitrate reduces blood pressure and increases blood flow to the heart, alleviating symptoms of angina pectoris [1].

Uses and Applications

The primary use of erythrityl tetranitrate is in the treatment of angina pectoris. It is also sometimes used for other conditions characterized by reduced blood flow to the heart, such as myocardial ischemia. Erythrityl tetranitrate may be prescribed as a prophylactic medication to prevent angina attacks or as an acute treatment for chest pain.

Off-Label Uses

In addition to its approved indications, erythrityl tetranitrate may be used off-label for other cardiovascular conditions, such as heart failure or pulmonary hypertension. However, the safety and efficacy of these uses have not been fully established.

Dosage and Administration

Erythrityl tetranitrate is typically administered orally or sublingually. The usual starting dose for angina prophylaxis is 5-10 mg taken two to three times daily. For acute angina attacks, a sublingual dose of 2.5-5 mg may be used. The dosage may be adjusted based on individual response and tolerability. It is essential to follow the prescribed dosing schedule and not exceed the recommended dose to avoid the risk of adverse effects [2].

Interactions and Precautions

Erythrityl tetranitrate may interact with other medications, including phosphodiesterase type 5 inhibitors (e.g., sildenafil), blood pressure-lowering drugs, and other nitrates. These interactions can potentiate the hypotensive effects of erythrityl tetranitrate and increase the risk of adverse effects. Patients should inform their healthcare provider about all medications they are taking before starting erythrityl tetranitrate.

Precautions should be taken in patients with certain medical conditions, such as severe anemia, hypotension, or recent head trauma. Erythrityl tetranitrate should be used with caution in these populations, as it may worsen their condition or cause adverse effects.

Side Effects and Risks

Common side effects of erythrityl tetranitrate include headache, dizziness, lightheadedness, and flushing. These effects are usually mild and transient. However, more severe side effects can occur, such as severe hypotension, syncope, or allergic reactions. Patients should be monitored for signs of toxicity, such as methemoglobinemia or cyanosis, which can occur with excessive doses or prolonged use [3].

Erythrityl Tetranitrate as an Explosive

In addition to its medical use, erythrityl tetranitrate is known for its explosive properties. It is structurally similar to pentaerythritol tetranitrate (PETN), a commonly used explosive. ETN is sensitive to friction, impact, and high temperatures, making it a hazardous material to handle. Proper safety measures and regulations must be followed when manufacturing, storing, or transporting erythrityl tetranitrate.

Regulation and Legal Issues

Erythrityl tetranitrate is a regulated substance due to its potential for misuse as an explosive. In the United States, it is classified as a List I chemical under the Chemical Diversion and Trafficking Act. Manufacturers, distributors, and importers of erythrityl tetranitrate must comply with strict record-keeping and reporting requirements. The sale and possession of ETN may be restricted or prohibited in certain jurisdictions.

Environmental Impact

The environmental impact of erythrityl tetranitrate is not well-studied. As a synthetic organic compound, it may have the potential for environmental persistence and bioaccumulation. Proper disposal methods should be followed to minimize ecological risks. More research is needed to fully understand the environmental fate and effects of ETN.

References

1. Münzel, T., & Gori, T. (2009). Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Current Opinion in Pharmacology, 9(2), 230-235. https://doi.org/10.1016/j.coph.2009.02.002
2. Parker, J. O., & Parker, J. D. (1998). Nitrate therapy for stable angina pectoris. New England Journal of Medicine, 338(8), 520-531. https://doi.org/10.1056/NEJM199802193380807
3. Münzel, T., Steven, S., & Daiber, A. (2014). Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vascular Pharmacology, 63(3), 105-113. https://doi.org/10.1016/j.vph.2014.09.002